AbbVie Inc.

ABBVleader

AbbVie is a global biopharmaceutical company that was spun off from Abbott Laboratories in 2013. While Humira was once the world's best-selling drug, AbbVie has successfully navigated its patent cliff with Skyrizi and Rinvoq, which are on track to exceed Humira's peak revenue combined.

⇄ Compare

Produk & Pendapatan

Pangsa Pendapatan Produk

Komposisi Pendapatan ($56.3B)

Data statis (memuat keuangan langsung…)

Immunology (45%)

Aesthetics/Neuroscience (25%)

Oncology (15%)

Eye Care & Other (15%)

Komposisi segmen dan pelanggan utama

Detail produk

Skyrizi / Rinvoq35%

Next-generation immunology biologics replacing Humira revenue

Humira20%

Anti-TNF biologic for rheumatoid arthritis and autoimmune diseases (declining post-LOE)

Botox / Aesthetics25%

Allergan aesthetics portfolio including Botox, Juvederm, and CoolSculpting

Hubungan Rantai Pasok

Pesaing

Eli Lilly and Company

Immunology and oncology drugs

Dampak: Key therapeutic competitor

Regeneron Pharmaceuticals

Dupixent vs Skyrizi/Rinvoq

Dampak: Direct immunology competition

Pfizer Inc.

Broad pharmaceutical portfolio overlap

Dampak: Major pharma rival

Konteks makro dan pasar

제약 / 바이오Berita sektor

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Katalis mendatang

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Berita terkini

Memuat berita...

Analisis AI

Klik "Dapatkan Analisis AI" untuk analisis rantai pasok AbbVie Inc..

Info Perusahaan

Kantor Pusat

North Chicago, Illinois, USA

Didirikan

2013

Karyawan

50,000+

Situs Web

abbvie.com

Gambaran umum sektor — 제약 / 바이오

Berita sektor